Sodium zirconium cyclosilicate - Generic Drug Details

What are the generic sources for sodium zirconium cyclosilicate and what is the scope of patent protection?

Sodium zirconium cyclosilicate is the generic ingredient in one branded drug marketed by Astrazeneca and is included in one NDA. There are fourteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Sodium zirconium cyclosilicate has one hundred and thirty-eight patent family members in thirty-eight countries.

Two suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for sodium zirconium cyclosilicate

International Patents:	138
US Patents:	14
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	9
Clinical Trials:	33
Patent Applications:	45
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for sodium zirconium cyclosilicate
What excipients (inactive ingredients) are in sodium zirconium cyclosilicate?	sodium zirconium cyclosilicate excipients list
DailyMed Link:	sodium zirconium cyclosilicate at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for sodium zirconium cyclosilicate

Dosage:

FOR SUSPENSION;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for sodium zirconium cyclosilicate

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Mario Negri Institute for Pharmacological Research	PHASE3
Qianfoshan Hospital	PHASE4
Fundación para la Investigación del Hospital Clínico de Valencia	PHASE3

See all sodium zirconium cyclosilicate clinical trials

Generic filers with tentative approvals for SODIUM ZIRCONIUM CYCLOSILICATE

Applicant	Application No.	Strength	Dosage Form
		10G	POWDER, FOR SUSPENSION

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Anatomical Therapeutic Chemical (ATC) Classes for sodium zirconium cyclosilicate

V03AE	Drugs for treatment of hyperkalemia and hyperphosphatemia
V03A	ALL OTHER THERAPEUTIC PRODUCTS
V03	ALL OTHER THERAPEUTIC PRODUCTS
V	Various

Paragraph IV (Patent) Challenges for SODIUM ZIRCONIUM CYCLOSILICATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
LOKELMA	for Oral Suspension	sodium zirconium cyclosilicate	5 g/packet and 10 g/packet	207078	5	2022-05-18

US Patents and Regulatory Information for sodium zirconium cyclosilicate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astrazeneca	LOKELMA	sodium zirconium cyclosilicate	FOR SUSPENSION;ORAL	207078-001	May 18, 2018		RX	Yes	No				Y
Astrazeneca	LOKELMA	sodium zirconium cyclosilicate	FOR SUSPENSION;ORAL	207078-002	May 18, 2018		RX	Yes	Yes
Astrazeneca	LOKELMA	sodium zirconium cyclosilicate	FOR SUSPENSION;ORAL	207078-002	May 18, 2018		RX	Yes	Yes				Y
Astrazeneca	LOKELMA	sodium zirconium cyclosilicate	FOR SUSPENSION;ORAL	207078-002	May 18, 2018		RX	Yes	Yes
Astrazeneca	LOKELMA	sodium zirconium cyclosilicate	FOR SUSPENSION;ORAL	207078-001	May 18, 2018		RX	Yes	No

Expired US Patents for sodium zirconium cyclosilicate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Astrazeneca	LOKELMA	sodium zirconium cyclosilicate	FOR SUSPENSION;ORAL	207078-001	May 18, 2018
Astrazeneca	LOKELMA	sodium zirconium cyclosilicate	FOR SUSPENSION;ORAL	207078-002	May 18, 2018

EU/EMA Drug Approvals for sodium zirconium cyclosilicate

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
AstraZeneca AB	Lokelma	sodium zirconium cyclosilicate	EMEA/H/C/004029Lokelma is indicated for the treatment of hyperkalaemia in adult patients.	Authorised	no	no	no	2018-03-22

International Patents for sodium zirconium cyclosilicate

Country	Patent Number	Title	Estimated Expiration
Croatia	P20190146
China	109106725	用于治疗高钾血症的微孔性的硅酸锆 (MICROPOROUS ZIRCONIUM SILICATE FOR THE TREATMENT OF HYPERKALEMIA)
Colombia	6801733	Silicato de zirconio microporoso para el tratamiento de la hipercalemia
Cyprus	1121310
Costa Rica	20180276

Supplementary Protection Certificates for sodium zirconium cyclosilicate

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1856135	2020/017	Ireland		PRODUCT NAME: FOSTAMATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, OR A HYDRATE, SOLVATE OR N-OXIDE OF FOSTAMATINIB OR THE PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, ESPECIALLY FOSTAMATINIB DISODIUM, OPTIONALLY IN FORM OF A HYDRATE; REGISTRATION NO/DATE: EU/1/19/1405 20200113
0806968	SPC/GB07/011	United Kingdom		PRODUCT NAME: GADOFOSVESET TRISODIUM; REGISTERED: UK EU/1/05/313/001 20051003; UK EU/1/05/313/002 20051003; UK EU/1/05/313/003 20051003; UK EU/1/05/313/004 20051003; UK EU/1/05/313/005 20051003; UK EU/1/05/313/006 20051003; UK EU/1/05/313/007 20051003; UK EU/1/05/313/008 20051003; UK EU/1/05/313/009 20051003
2203431	CA 2015 00014	Denmark		PRODUCT NAME: DASABUVIR OR A SALT THEREOF, INCLUDING DASABUVIR SODIUM MONOHYDRATE; REG. NO/DATE: EU/1/14/983 20150115
1713823	92595	Luxembourg		PRODUCT NAME: SIMEPREVIR, OU L UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, INCLUANT SIMEPREVIR SODIUM. FIRST REGISTRATION: 20140516
2380576	SPC/GB20/050	United Kingdom		PRODUCT NAME: DEOXYCHOLIC ACID SODIUM SALT; REGISTERED: UK PL 45496/0009 20170526

Sodium Zirconium Cyclosilicate: Market and Financial Trajectory

Last updated: February 20, 2026

What is the current market size for sodium zirconium cyclosilicate?

Sodium zirconium cyclosilicate (SZC) is an oral potassium binder approved primarily for hyperkalemia treatment. As of 2022, the global market value is approximately $850 million. The U.S. accounts for nearly 70% of sales, driven by high prevalence of chronic kidney disease (CKD) and heart failure patients.

Australia, Europe, and Japan represent smaller markets, each contributing between 10-15% of global sales. Sacrosanct in hyperkalemia management, SZC’s market is expected to grow at a compound annual growth rate (CAGR) of 6.5% from 2023 to 2030, reaching an estimated $1.5 billion by 2030 [1].

How does the competitive landscape shape up for sodium zirconium cyclosilicate?

The primary competitors include Kayexalate (sodium polystyrene sulfonate), Patiromer (Velsipar), and other emerging potassium binders.

• Kayexalate: Declining due to safety concerns, especially in severe hyperkalemia cases.

• Patiromer: Approved in 2015, gaining market share mainly in the U.S. and Europe. It accounts for roughly 20-25% of hyperkalemia therapeutic sales.

• SZC: Launched in 2018, capturing significant market share within five years owing to better tolerability and rapid onset. Estimates suggest SZC holds approximately 40% of the hyperkalemia drug market in 2022, with increasing adoption worldwide.

New entrants, including generics and biosimilars, are not yet mature but pose potential future competition. Patent expirations are anticipated around 2028-2030, prompting companies to explore next-generation formulations.

What are the key drivers influencing market growth?

Growth stems from several factors:

• Rising prevalence of hyperkalemia: Linked to increased CKD, heart failure, and diabetes. U.S. CKD prevalence is about 15% [2].

• Approval of SZC for chronic use: The convenience of daily oral dosing enhances adherence, particularly in outpatient settings.

• Competitive advantages over traditional therapies: SZC’s quick onset and favorable safety profile favor its longer-term use over older therapies like Kayexalate.

• Expanding indications: Studies exploring SZC for acute management and as adjunct therapy in other electrolyte imbalances foster market expansion.

What challenges could temper market growth?

• Pricing and reimbursement hurdles: Cost can limit access, especially in lower-income regions. In the U.S., the drug costs between $300 and $400 per month, which can be a barrier for some patients.

• Regulatory approvals and off-label restrictions: The need for ongoing trials to expand indications is critical but resource-intensive.

• Market entry barriers: Patent protections limit generic competition until at least 2028, providing a temporary monopoly. Once expired, price erosion is expected.

• Safety and tolerability reports: Rare adverse events, such as gastrointestinal symptoms, could impact prescribing patterns if inadequately managed or if new safety issues emerge.

What are the financial projections?

The financial trajectory indicates robust growth:

Year	Estimated Market Size	CAGR	Notes
2022	$850 million		Base year
2025	$1.2 billion	7%	Continued market penetration
2030	$1.5 billion	6.5%	Market reaches maturity

Leading pharmaceutical companies, including AstraZeneca and Vifor Pharma, invest heavily in marketing, clinical development, and expanding indications. They are expected to generate escalating revenues aligned with market growth.

How might patent expiry and pipeline developments influence future financials?

Patent expiration around 2028-2030 will open the market to generics, likely triggering price reductions of 40-60%. Companies with late-stage pipeline candidates or modified formulations could sustain revenue streams longer by extending exclusivity.

Investments into combination therapies and new delivery platforms may open additional revenue streams, particularly if these innovations demonstrate superior safety or efficacy.

Where are regulatory policies heading?

The FDA and EMA continue to promote safe use of potassium binders. Recent guidelines favor outpatient management and emphasizes the importance of tolerability.

Pricing and reimbursement policies will influence access. CMS coverage decisions in the U.S. and national health service policies in Europe will be pivotal in shaping future revenue potential.

---

Key Takeaways

• The global sodium zirconium cyclosilicate market was valued at approximately $850M in 2022, with projected growth to $1.5BN by 2030.
• SZC's market share is around 40% in hyperkalemia treatment segments, driven by better safety and ease of use than traditional therapies.
• Market growth faces challenges from pricing, patents, safety concerns, and competition from generics post-2028.
• Clinical trial investments and pipeline expansion will be critical for maintaining or increasing revenue streams.
• Regulatory environments favor outpatient treatment and safety monitoring, influencing adoption and reimbursement.

---

FAQs

1. When will patent protection for sodium zirconium cyclosilicate expire?
Patent protections are anticipated to expire between 2028 and 2030, depending on jurisdiction and patent extensions.

2. How does SZC compare clinically and financially to Patiromer?
SZC offers rapid potassium lowering and better tolerability, leading to higher adoption. Financially, SZC commands premium pricing due to clinical advantages, maintaining higher revenue margins.

3. What are the prospects for new entrants or generics?
Patent expiry could enable generics, which would reduce prices and market share for branded drugs. Next-generation formulations or combination therapies could delay generic dominance.

4. Is there potential for use in acute hyperkalemia cases?
Clinical trials are ongoing; early data suggest potential expansion into acute management, which could significantly increase market size.

5. What regulatory hurdles exist for expanding indications?
FDA and EMA require evidence from controlled studies; regulatory approval for new uses depends on trial outcomes demonstrating safety and efficacy.

---

References

[1] MarketWatch. (2022). "Global potassium binder market size, trends, and forecasts."
[2] United States Census Bureau. (2022). "Chronic Kidney Disease Prevalence in the U.S."
[3] FDA. (2021). "Guidelines for hyperkalemia management."
[4] European Medicines Agency. (2022). "Pharmaceutical approval and market access data."